Quantitative analysis for Avalo Therapeutics, Inc. (AVTX) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Buy (65.0) (grade B). 30 signals analyzed (24 differentiated alt-data).
AVTX stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-04-29 | $13.53 | $12.51 | $13.20 |
| 2026-05-11 | $22.02 | $19.80 | $20.25 |
| 2026-05-21 | $17.10 | $15.92 | $16.60 |
| 2026-06-03 | $14.71 | $13.65 | $13.74 |
| 2026-06-15 | $15.23 | $14.51 | $14.60 |
| 2026-06-26 | $18.46 | $17.63 | $18.20 |
| 2026-07-09 | $20.02 | $19.12 | $19.95 |
| 2026-07-21 | $19.01 | $18.09 | $18.82 |
| 2026-07-31 | $19.73 | $18.24 | $18.25 |
| 2026-08-12 | $19.77 | $19.27 | $19.55 |
| 2026-08-24 | $19.86 | $18.88 | $19.27 |
| 2026-09-03 | $19.57 | $18.73 | $19.00 |
How Avalo Therapeutics, Inc. stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| IMRX | Immuneering Corporation | $182M | 36.0 |
| ALMR | Alamar Biosciences, Inc. | $189M | — |
| IFRX | InflaRx N.V. | $176M | 38.0 |
| ARTV | Artiva Biotherapeutics, Inc. | $194M | 66.0 |
View all Health Care stocks by valuation and signals →
Avalo Therapeutics, Inc. (AVTX) scores Buy (65.0), and the composite conceals a 92-point disagreement between its dimensions. It is strongest on competitive moat at 94 and earnings quality at 82, and weakest on analyst consensus at 2. A stock can carry competitive moat that high while analyst consensus sits at 2; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| competitive moat | 94 |
| earnings quality | 82 |
| ML forecast | 76 |
| valuation | 72 |
| AI Alpha (gem) | 68 |
| technicals | 65 |
| analyst consensus | 2 |
StoQuant analyzes 30 signals (24 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on Avalo Therapeutics, Inc. (AVTX): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/AVTX"><img src="https://stoquant.com/badge/AVTX.svg" alt="Avalo Therapeutics, Inc. (AVTX) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.